155 related articles for article (PubMed ID: 29779953)
21. Determination of transit dose profile for a (192)Ir HDR source.
Fonseca GP; Rubo RA; Minamisawa RA; dos Santos GR; Antunes PC; Yoriyaz H
Med Phys; 2013 May; 40(5):051717. PubMed ID: 23635265
[TBL] [Abstract][Full Text] [Related]
22. The transit dose component of high dose rate brachytherapy: direct measurements and clinical implications.
Bastin KT; Podgorsak MB; Thomadsen BR
Int J Radiat Oncol Biol Phys; 1993 Jul; 26(4):695-702. PubMed ID: 8331003
[TBL] [Abstract][Full Text] [Related]
23. The contribution from transit dose for (192)Ir HDR brachytherapy treatments.
Fonseca GP; Landry G; Reniers B; Hoffmann A; Rubo RA; Antunes PC; Yoriyaz H; Verhaegen F
Phys Med Biol; 2014 Apr; 59(7):1831-44. PubMed ID: 24625517
[TBL] [Abstract][Full Text] [Related]
24. Mechanical evaluation of the Bravos afterloader system for HDR brachytherapy.
Bellezzo M; Baeza JA; Voncken R; Reniers B; Verhaegen F; Fonseca GP
Brachytherapy; 2019; 18(6):852-862. PubMed ID: 31327634
[TBL] [Abstract][Full Text] [Related]
25. Transpapillary iridium-192 wire in the treatment of malignant bile duct obstruction.
Levitt MD; Laurence BH; Cameron F; Klemp PF
Gut; 1988 Feb; 29(2):149-52. PubMed ID: 2831118
[TBL] [Abstract][Full Text] [Related]
26. [Endoscopic intraductal radiotherapy of high bile-duct carcinoma].
Phillip J; Hagenmüller F; Manegold K; Szepesi S; Classen M
Dtsch Med Wochenschr; 1984 Mar; 109(11):422-6. PubMed ID: 6697900
[TBL] [Abstract][Full Text] [Related]
27. Independent assessment of source transit time for the BEBIG SagiNova® cobalt-60 high dose rate brachytherapy afterloader.
Kanani A; Karbasi S; Mosleh-Shirazi MA
Australas Phys Eng Sci Med; 2019 Dec; 42(4):913-919. PubMed ID: 31452058
[TBL] [Abstract][Full Text] [Related]
28. Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma.
González González D; Gouma DJ; Rauws EA; van Gulik TM; Bosma A; Koedooder C
Ann Oncol; 1999; 10 Suppl 4():215-20. PubMed ID: 10436826
[TBL] [Abstract][Full Text] [Related]
29. Endoscopic management of inoperable cholangiocarcinoma using iridium-192.
Ede RJ; Williams SJ; Hatfield AR; McIntyre S; Mair G
Br J Surg; 1989 Aug; 76(8):867-9. PubMed ID: 2548655
[TBL] [Abstract][Full Text] [Related]
30. Role of intraluminal brachytherapy as a palliative treatment modality in unresectable cholangiocarcinomas.
Chigurupalli K; Vashistha A
J Cancer Res Ther; 2021; 17(1):10-12. PubMed ID: 33723125
[TBL] [Abstract][Full Text] [Related]
31. Near-catheter dosimetry of a HDR brachytherapy source using Gafchromic film.
Odgers D; Haque M
Australas Phys Eng Sci Med; 2013 Jun; 36(2):159-66. PubMed ID: 23479182
[TBL] [Abstract][Full Text] [Related]
32. HDR 192Ir source speed measurements using a high speed video camera.
Fonseca GP; Viana RS; Podesta M; Rubo RA; de Sales CP; Reniers B; Yoriyaz H; Verhaegen F
Med Phys; 2015 Jan; 42(1):412-5. PubMed ID: 25563281
[TBL] [Abstract][Full Text] [Related]
33. Design and characterization of a new high-dose-rate brachytherapy Valencia applicator for larger skin lesions.
Candela-Juan C; Niatsetski Y; van der Laarse R; Granero D; Ballester F; Perez-Calatayud J; Vijande J
Med Phys; 2016 Apr; 43(4):1639. PubMed ID: 27036563
[TBL] [Abstract][Full Text] [Related]
34. Transit dose of an Ir-192 high dose rate brachytherapy stepping source.
Wong TP; Fernando W; Johnston PN; Bubb IF
Phys Med Biol; 2001 Feb; 46(2):323-31. PubMed ID: 11229717
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of direct-conversion flat-panel detector system as a quality assurance tool for high-dose-rate 192Ir source.
Miyahara Y; Kitagaki H; Nishimura T; Itakura K; Takahashi S; Yokokawa M; Uchida N; Inomata T
J Appl Clin Med Phys; 2015 Jan; 16(1):5068. PubMed ID: 25679163
[TBL] [Abstract][Full Text] [Related]
36. Interstitial rotating shield brachytherapy for prostate cancer.
Adams QE; Xu J; Breitbach EK; Li X; Enger SA; Rockey WR; Kim Y; Wu X; Flynn RT
Med Phys; 2014 May; 41(5):051703. PubMed ID: 24784369
[TBL] [Abstract][Full Text] [Related]
37. The evaluation of a 2D diode array in "magic phantom" for use in high dose rate brachytherapy pretreatment quality assurance.
Espinoza A; Petasecca M; Fuduli I; Howie A; Bucci J; Corde S; Jackson M; Lerch ML; Rosenfeld AB
Med Phys; 2015 Feb; 42(2):663-673. PubMed ID: 28102606
[TBL] [Abstract][Full Text] [Related]
38. Cholangiocarcinoma: CT-guided High-Dose Rate Brachytherapy (CT-HDRBT) for Limited (<4 cm) and Large (>4 cm) Tumors.
Jonczyk M; Collettini F; Schnapauff D; Geisel D; Böning G; Feldhaus F; Denecke T; Wieners G; Hamm B; Gebauer B
Anticancer Res; 2018 Oct; 38(10):5843-5852. PubMed ID: 30275209
[TBL] [Abstract][Full Text] [Related]
39. Measurement of transit time of a remote after-loading high dose rate brachytherapy source.
Sahoo N
Med Phys; 2001 Aug; 28(8):1786-90. PubMed ID: 11548950
[TBL] [Abstract][Full Text] [Related]
40. Dosimetric characterization of the M-15 high-dose-rate Iridium-192 brachytherapy source using the AAPM and ESTRO formalism.
Ho Than MT; Munro Iii JJ; Medich DC
J Appl Clin Med Phys; 2015 May; 16(3):5270. PubMed ID: 26103489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
